Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 297

1.

[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].

Liu H, Fan ZP, Jiang QL, Huang F, Zhou HS, Zhang X, Yu GP, Wu MQ, Sun J, Liu QF.

Zhonghua Nei Ke Za Zhi. 2012 Nov;51(11):880-4. Chinese.

PMID:
23291027
[PubMed - indexed for MEDLINE]
2.

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.

Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, Zhang Y, Huang F, Zhou H, Fan Z, Tu S, Li Y, Guo X, Yu G, Liu Q.

J Hematol Oncol. 2013 Feb 8;6:15. doi: 10.1186/1756-8722-6-15.

PMID:
23394705
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.

J Clin Oncol. 2013 Oct 1;31(28):3549-56. doi: 10.1200/JCO.2013.48.8114. Epub 2013 Aug 26.

PMID:
23980086
[PubMed - indexed for MEDLINE]
Free Article
4.

Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.

Raida L, Tucek P, Faber E, Vondrakova J, Rusinakova Z, Skoumalova I, Hubacek J, Jarosova M, Katrincsakova B, Pikalova Z, Kurfurst P, Indrak K.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Dec;155(4):327-32. doi: 10.5507/bp.2011.040.

PMID:
22336644
[PubMed - indexed for MEDLINE]
Free Article
5.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):468-76.

PMID:
12374451
[PubMed - indexed for MEDLINE]
6.

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.

Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF.

J Hematol Oncol. 2010 Oct 6;3:36. doi: 10.1186/1756-8722-3-36.

PMID:
20925957
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE.

Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900. doi: 10.1016/j.bbmt.2010.09.022. Epub 2010 Oct 11.

PMID:
20946966
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE.

Biol Blood Marrow Transplant. 2008 Jun;14(6):672-84. doi: 10.1016/j.bbmt.2008.03.009.

PMID:
18489993
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.

Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9.

PMID:
22079471
[PubMed - indexed for MEDLINE]
10.

Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.

Tang W, Wang L, Zhao WL, Chen YB, Shen ZX, Hu J.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1555-61. doi: 10.1016/j.bbmt.2011.04.003. Epub 2011 Apr 16.

PMID:
21549217
[PubMed - indexed for MEDLINE]
11.

Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.

Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A, Setia R, Katewa S.

Biol Blood Marrow Transplant. 2013 Mar;19(3):492-5. doi: 10.1016/j.bbmt.2012.11.007. Epub 2012 Nov 15.

PMID:
23160007
[PubMed - indexed for MEDLINE]
12.

Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.

Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.

Bone Marrow Transplant. 2001 Feb;27(4):349-54.

PMID:
11313663
[PubMed - indexed for MEDLINE]
Free Article
13.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.

PMID:
23562738
[PubMed - indexed for MEDLINE]
14.

Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.

Bartelink IH, van Reij EM, Gerhardt CE, van Maarseveen EM, de Wildt A, Versluys B, Lindemans CA, Bierings MB, Boelens JJ.

Biol Blood Marrow Transplant. 2014 Mar;20(3):345-53. doi: 10.1016/j.bbmt.2013.11.027. Epub 2013 Dec 4.

PMID:
24315842
[PubMed - indexed for MEDLINE]
15.

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.

Bone Marrow Transplant. 2000 Oct;26(7):711-6.

PMID:
11042650
[PubMed - indexed for MEDLINE]
Free Article
16.

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1490-6. doi: 10.1016/j.bbmt.2011.02.007. Epub 2011 Feb 18.

PMID:
21338705
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group.

Ann Hematol. 2003 Jun;82(6):336-42. Epub 2003 May 1.

PMID:
12728337
[PubMed - indexed for MEDLINE]
18.

[Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].

Tong XZ, Xu DR, Zou WY, Li J, Luo SK, Peng AH, Zhang GC, Zheng D.

Ai Zheng. 2007 Aug;26(8):914-8. Chinese.

PMID:
17697559
[PubMed - indexed for MEDLINE]
19.

Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant.

Eroglu C, Pala C, Kaynar L, Yaray K, Aksozen MT, Bankir M, Zararsız G, Orhan O, Gündog M, Yıldız OG, Eser B, Cetin M, Unal A.

Leuk Lymphoma. 2013 Nov;54(11):2474-9. doi: 10.3109/10428194.2013.779691. Epub 2013 Mar 27.

PMID:
23442062
[PubMed - indexed for MEDLINE]
20.

The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.

Rosales F, Naparstek E, Varadi G, Or R, Slavin S, Nagler A.

Leuk Res. 1999 Oct;23(10):947-52.

PMID:
10573141
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk